The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The role of next-generation BTK inhibitors in the treatment of CLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses the role of next-generation Bruton’s tyrosine kinase (BTK) inhibitors, including acalabrutinib, zanubrutinib, and pirtobrutinib, in the treatment of chronic lymphocytic leukemia (CLL). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
